| scholarly article | Q13442814 |
| P8978 | DBLP publication ID | journals/bib/VilarH17 |
| P356 | DOI | 10.1093/BIB/BBW048 |
| P932 | PMC publication ID | 6078166 |
| P698 | PubMed publication ID | 27273288 |
| P50 | author | George Hripcsak | Q32634180 |
| P2093 | author name string | Santiago Vilar | |
| P2860 | cites work | Semantic similarity in biomedical ontologies | Q21145359 |
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| Data-driven prediction of drug effects and interactions | Q24599300 | ||
| NCBI GEO: mining tens of millions of expression profiles--database and tools update | Q24675443 | ||
| Identification of putative gene based markers of renal toxicity | Q24811608 | ||
| Pharmacogenomics of adverse drug reactions | Q27015820 | ||
| PREDICT: a method for inferring novel drug indications with application to personalized medicine | Q27137071 | ||
| Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors | Q27764855 | ||
| Quantitative monitoring of gene expression patterns with a complementary DNA microarray | Q27861102 | ||
| Functional discovery via a compendium of expression profiles | Q27938962 | ||
| Inferring genetic networks and identifying compound mode of action via expression profiling | Q28185053 | ||
| Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure | Q28222762 | ||
| mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass | Q28239563 | ||
| Estimating the cost of new drug development: is it really 802 million dollars? | Q28300812 | ||
| Drug-induced regulation of target expression | Q28475443 | ||
| Human disease-drug network based on genomic expression profiles | Q28475892 | ||
| Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance | Q40225720 | ||
| Analysis of drug-induced effect patterns to link structure and side effects of medicines | Q40363457 | ||
| A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity | Q40379300 | ||
| Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects | Q40713580 | ||
| Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. | Q40821953 | ||
| Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs | Q41962127 | ||
| DINIES: drug-target interaction network inference engine based on supervised analysis. | Q42044276 | ||
| INDI: a computational framework for inferring drug interactions and their associated recommendations | Q42280497 | ||
| Predicting ligand binding modes from neural networks trained on protein-ligand interaction fingerprints | Q43528957 | ||
| Methapyrilene toxicity: anchorage of pathologic observations to gene expression alterations. | Q44109092 | ||
| Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment | Q45007602 | ||
| Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space | Q46181348 | ||
| APIF: a new interaction fingerprint based on atom pairs and its application to virtual screening. | Q48014010 | ||
| Encoding protein-ligand interaction patterns in fingerprints and graphs. | Q51252993 | ||
| Comparative analysis of gene expression profiles between the normal human cartilage and the one with endemic osteoarthritis. | Q54527217 | ||
| Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy. | Q54609129 | ||
| Molecular similarity in medicinal chemistry. | Q54708065 | ||
| Gene expression analysis reveals chemical-specific profiles | Q74100166 | ||
| Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation | Q75447880 | ||
| Identification of toxicologically predictive gene sets using cDNA microarrays | Q77292517 | ||
| Drug-induced changes in P450 enzyme expression at the gene expression level: a new dimension to the analysis of drug-drug interactions | Q79374421 | ||
| Improving detection of adverse effects of marketed drugs | Q80628087 | ||
| Cancer genomics: indicators for drug response from sequencing | Q84402470 | ||
| Personalized pharmacogenomics: predicting efficacy and adverse drug reactions | Q38217661 | ||
| Molecular fingerprint similarity search in virtual screening | Q38240827 | ||
| A semantic web ontology for small molecules and their biological targets | Q38374255 | ||
| Similarity-based search of model organism, disease and drug effect phenotypes | Q38415033 | ||
| Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity. | Q38434869 | ||
| Using genomics to help predict drug interactions | Q38449747 | ||
| Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study | Q39608974 | ||
| Effectiveness of 2D fingerprints for scaffold hopping | Q39765581 | ||
| Mapping adverse drug reactions in chemical space. | Q39881783 | ||
| Identifying network of drug mode of action by gene expression profiling | Q39889042 | ||
| Inferring new drug indications using the complementarity between clinical disease signatures and drug effects. | Q40168508 | ||
| Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators | Q40225712 | ||
| Systematic drug repositioning based on clinical side-effects | Q28478506 | ||
| Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer | Q28480572 | ||
| Assessing drug target association using semantic linked data | Q28480992 | ||
| Recycling side-effects into clinical markers for drug repositioning | Q28482438 | ||
| Detection of drug-drug interactions by modeling interaction profile fingerprints | Q28487875 | ||
| The Connectivity Map: a new tool for biomedical research | Q28530408 | ||
| Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling | Q28548219 | ||
| Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action | Q28564857 | ||
| Identification of ubiquitin ligases required for skeletal muscle atrophy | Q28582211 | ||
| Similarity-based modeling in large-scale prediction of drug-drug interactions | Q28647954 | ||
| Novel data-mining methodologies for adverse drug event discovery and analysis | Q28681788 | ||
| A side effect resource to capture phenotypic effects of drugs | Q29387552 | ||
| The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease | Q29547614 | ||
| Drug target identification using side-effect similarity | Q29615103 | ||
| Can the pharmaceutical industry reduce attrition rates? | Q29616077 | ||
| Relating protein pharmacology by ligand chemistry | Q29617492 | ||
| The SIDER database of drugs and side effects | Q30002337 | ||
| Drug discovery in the age of systems biology: the rise of computational approaches for data integration. | Q30485238 | ||
| The use of web ontology languages and other semantic web tools in drug discovery | Q30485603 | ||
| Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease | Q30526431 | ||
| Transcriptional data: a new gateway to drug repositioning? | Q30557854 | ||
| Structural protein-ligand interaction fingerprints (SPLIF) for structure-based virtual screening: method and benchmark study | Q30587389 | ||
| Evaluation of analytical methods for connectivity map data | Q30591185 | ||
| Drug repositioning: a machine-learning approach through data integration | Q30651571 | ||
| Gene expression omnibus: microarray data storage, submission, retrieval, and analysis | Q31057685 | ||
| Molecular similarity: a key technique in molecular informatics | Q31126264 | ||
| Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions | Q33196625 | ||
| Optimizing fragment and scaffold docking by use of molecular interaction fingerprints | Q33269786 | ||
| Molecular subsets in the gene expression signatures of scleroderma skin | Q33354088 | ||
| Biological spectra analysis: Linking biological activity profiles to molecular structure | Q33569085 | ||
| Identification of small molecules enhancing autophagic function from drug network analysis | Q33712703 | ||
| Systematic evaluation of drug-disease relationships to identify leads for novel drug uses | Q33718713 | ||
| SuperPred: update on drug classification and target prediction | Q33860868 | ||
| Predicting drug side-effect profiles: a chemical fragment-based approach | Q33903536 | ||
| Predicting adverse drug reactions using publicly available PubChem BioAssay data | Q33912477 | ||
| Discovery and preclinical validation of drug indications using compendia of public gene expression data | Q33995422 | ||
| Discovery of drug mode of action and drug repositioning from transcriptional responses | Q34093341 | ||
| Reoptimization of MDL keys for use in drug discovery | Q34160151 | ||
| Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties | Q34235803 | ||
| Applications of Connectivity Map in drug discovery and development | Q34378751 | ||
| Similarity-based modeling applied to signal detection in pharmacovigilance. | Q34413023 | ||
| New uses for old drugs | Q34661227 | ||
| The genetic basis of variability in drug responses | Q34741545 | ||
| Systematic evaluation of connectivity map for disease indications | Q34781421 | ||
| The cost of adverse drug reactions | Q35076575 | ||
| Exploiting drug-disease relationships for computational drug repositioning | Q35109885 | ||
| Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity assessment | Q35187094 | ||
| An overview of molecular fingerprint similarity search in virtual screening | Q35838408 | ||
| Predicting drug response based on gene expression | Q35872206 | ||
| Large-scale prediction and testing of drug activity on side-effect targets | Q36059863 | ||
| Drug target prediction using adverse event report systems: a pharmacogenomic approach. | Q36218106 | ||
| Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan | Q36481670 | ||
| Drug-drug interaction through molecular structure similarity analysis. | Q36500491 | ||
| Hospitalisations and emergency department visits due to drug-drug interactions: a literature review | Q36677190 | ||
| SuperPred: drug classification and target prediction | Q36749406 | ||
| Predicting drug-target interactions using restricted Boltzmann machines | Q36960730 | ||
| Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records | Q36972534 | ||
| The use of protein-ligand interaction fingerprints in docking. | Q37144273 | ||
| Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. | Q37198083 | ||
| Postmarketing adverse drug reactions: A duty to report? | Q37207579 | ||
| Informatics confronts drug-drug interactions | Q37257012 | ||
| Similarity searching using 2D structural fingerprints | Q37788600 | ||
| Literature mining, ontologies and information visualization for drug repurposing | Q37895399 | ||
| Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research | Q37973656 | ||
| Advances in 2D fingerprint similarity searching | Q38028554 | ||
| Pharmacogenomics of adverse drug reactions: implementing personalized medicine | Q38036150 | ||
| Fingerprint design and engineering strategies: rationalizing and improving similarity search performance | Q38054132 | ||
| Similarity-based machine learning methods for predicting drug-target interactions: a brief review | Q38128158 | ||
| P433 | issue | 4 | |
| P921 | main subject | drug interaction | Q718753 |
| P304 | page(s) | 670-681 | |
| P577 | publication date | 2016-06-05 | |
| P1433 | published in | Briefings in Bioinformatics | Q4967031 |
| P1476 | title | The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection and drug-drug interactions | |
| P478 | volume | 18 |
| Q89665960 | A Novel Approach for Drug-Target Interactions Prediction Based on Multimodal Deep Autoencoder |
| Q52593454 | A two-tiered unsupervised clustering approach for drug repositioning through heterogeneous data integration. |
| Q45943458 | DDR: Efficient computational method to predict drug-target interactions using graph mining and machine learning approaches. |
| Q64072607 | From single drug targets to synergistic network pharmacology in ischemic stroke |
| Q55329477 | Predicting potential drug-drug interactions on topological and semantic similarity features using statistical learning. |
| Q57002754 | Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology |
| Q37694044 | Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis |
Search more.